Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bigd, was todays news - the second part of the two-parts that
you were suggesting?
This is what XKEM should do to get rid of shorting!!!
Silver Screen Studios, Inc. implements Shareholders
Integrity Plan to address share imbalance and makes provisions to
migrate to NASDAQ Small Cap Market.
Shareholders Integrity Plan Objective:
Our management in an effort to protect the integrity of our
shareholders investment has adopted a Shareholders Integrity Plan
("SIP") and makes provisions to move to NASDAQ Small Cap Market once
Reg. E Funds are capitalized.
Shareholders Integrity Plan: Phase I
The SIP is the equivalent to the Shareholders Rights Plans as
designed by the law firm of Wachtell, Lipton, Rosen & Katz, i.e., the
Poison Pill. The Poison Pill has been upheld by the Delaware Courts as
a legal method to protect the shareholders interests in the company by
the board of directors acting in their business judgment. We feel the
SIP will protect our legal shareholders investment in our company as
we restructure into a profitable entity.
Implementation:
The management of SSSU has accessed a shareholders list as of
10-11-2006. This list was compared to the NOBO list as of 10-11-2006.
The shares in excess of the official total as compiled by the transfer
agent will be deemed "counterfeit shares".
Counterfeit Shares:
Any position deemed counterfeit will be deemed to be short a
failure to deliver share; each failure to deliver share outstanding of
SSSU shall be deemed liable as follows:
Counterfeit Shares Liability:
Each counterfeit share shall be liable to SSSU as follows:
(i) $1.00 per share in cash; plus
(ii) The 52 week high of $.041 multiplied by 7.77 multiplied by
the number of days the failure to deliver position has been open.
(iii) There are currently 102,767,486 shares unaccounted for.
Restructuring of Capital Structure:
Our management feels there is a significant failure to deliver
position in our stock and the NOBO list identified the extent of the
position. To protect our shareholders we are developing the share
exchange program with one of the Reg. E Funds that will place an
estimated value of $.10 to $.25 on the shares of SSSU.
Shareholder Benefits and Dividend Distribution:
We have developed the dividend program with one of the Reg. E.
Funds. Each Reg. E fund can raise up to $5.0 million per year exempt
from registration. We are working out the details of a dividend valued
in the range of $0.05-$0.12 per share.
TD Ameritrade:
We will have an update on Monday concerning the TD Ameritrade and
SBSH situation and the steps the company is taking to address the
problem. According to the NOBO list SSSU has 770 account holders at TD
Ameritrade who have been prevented buying shares in the company.
Summary:
The SIP will have no effect on our current shareholders. The SIP
will affect the imbalance in shares that have failed to be delivered
and remain open. We are exploring retaining a forensic accountant and
the DTC Position Report to identify each position and the owner of the
position and take actions to reward our legitimate shareholders with
the proceeds we recover.
About Global 1 Investment Corporation:
The family of funds we construct will have equity, fixed income,
real estate securities, mortgages, affordable housing and commercial
assets as investment opportunities for different classes of investors.
Disclaimer: The below disclaimer is incorporated by reference as
if fully set forth herein this as well as all media releases on SSS
behalf. The statements contained in this released are forward looking
and may or may not occur due to forces beyond the company's control.
Well, not tick-by-tick commentaries.
May be some additional info, that I could verify on my own.
I would be a fool for sure, if I would choose only selected
venues of information and ignore the rest.
no gibooanny, I am looking here for additional info
on XKEM and it's progress, past my own DD.
Instead, I find here bunch of day-traders with no
info and a lots of opinions(not the same as info).
piss off.
The only fact in your statement is that options were just granted to KEY management at these levels. However, they are not instead of base salary, but in addition too.
If your analysis of XKEM are as shrewd, as your understanding of my approach to XKEM, you are in deep trouble.
Your "soon" is already three months long.
He also said that the load is practically done, and that was two months ago.
All that with a costumer base of 80000. Ye, a realy good
strategy.
Med, mad, who cares.
Med, everyone could not be as smart as you.
What we need is the loan(s), then revenues, then profits.
jakuta, Did he tell you who is acting as an underwriter for the loan?
drif - Hey, Shakespeare, care about loan new?
drift. what happend, do not care about spelling anymore?
For the typo - replace "if" with "is".
For the rest, start reading current world events, a specially
what is going on in Nigeria with their elections power
struggle.
The government of Nigeria if a very transitory consept, at best.
Or the absents of the loan news.
Ye, ye, he stood up, you stood up. Where is the money?
Ganador, bull s..t, it is up only 1.64%
Who cares, where is the loan, where is the money?
Conference, conference, ... where is the loan,
where are the money?
Who cares what PIG says.
I am sure, a specially if you say so.
It is all well and nice, but where is the loan?
Pig, who cares.
Forum Timed for National Sickle Cell Disease Awareness Month; Is Largest
Conference on Disease and Its Ramifications
DALLAS, Sept. 21 -- Patient advocates, researchers,
clinicians, policy makers, and minority health leaders will address the state
of Sickle Cell Disease awareness and treatment in this country when the Sickle
Cell Disease Association of America (SCDAA) holds it 34th annual meeting
September 27-30 at the Hyatt Regency Dallas at Reunion in Dallas, Texas.
Taking place as National Sickle Cell Disease Awareness Month comes to a
close, SCDAA's convention -- Sickle Cell Disease: Meeting Unmet Needs -- is
the largest national forum focusing on the issues affecting the estimated
80,000 people in the U.S. with Sickle Cell Disease (SCD). An inherited blood
disorder affecting the red blood cells, SCD is a lifelong condition that
causes anemia and jaundice and can result in serious lung tissue damage,
stroke, and debilitating body pain. While there is no cure for SCD, early
diagnosis can help people live longer, healthier and more productive lives.
Because SCD lasts a lifetime, patients face many challenges, which is why
the 2006 SCDAA annual meeting will include over 40 educational sessions
focusing specifically on such topics as overcoming the disparities in how
adults with SCD receive treatment for acute and chronic pain, an area where
many patients are at risk for inadequate pain control. The forum will also
provide important new findings about treatment options for one of the
complications of SCD, iron overload, which occurs when patients receive
repeated blood transfusions. If left unchecked, the excess iron in the blood
can gather in the heart, liver, and other organs and may lead to organ damage.
SCDAA's national meeting also comes on the heels of new concerns about
discrimination against the more than 2.5 million Americans with sickle cell
trait (SCT), which is not a type of SCD. Although people with SCT are healthy,
when both parents have this trait, they have a 25 percent chance of having a
baby with sickle cell disease with each pregnancy. For this reason, a major
topic on the agenda will be educating the public about SCT and driving
awareness about the benefits of routine screenings for family planning
purposes.
"As a nation, we must elevate sickle cell disease as a priority concern,"
said Willarda V. Edwards, MD, president and COO of the association. "This
meeting will shine a light on the many issues now facing people with SCD so
that advocates and policy makers will have the insights to improve the
services and programs designed to prevent, detect and manage this condition at
its earliest stages and to support SCD patients throughout their lives."
Conference Addresses Latest Science; Provides Opportunity for People of
Dallas to Meet with National Leaders
The SCDAA national meeting will launch on September 27 with a series of
scientific presentations followed by an open reception for the people of
Dallas to learn about SCD. This free event will take place from 7:00 pm until
10:00 pm at the Hyatt Regency Dallas at Reunion in Dallas.
There will also be a blood drive on Saturday, September 30th from 10 a.m.
to 2 p.m. in Reunion Ballroom G-H as part of the SCDAA convention. Blood
transfusions are a part of the treatment of Sickle cell disease. It has been
shown to decrease pain crises and reduce the risk for stroke in children.
Continuing through September 30, the SCDAA convention will include
sessions on screenings of newborns, education of school children, pain
management, and new therapies in sickle cell disease. Some of the
conference highlights include:
* A special lecture by a scientist from the National Institutes of Health
(NIH) on new therapies in sickle cell disease -- September 27
* An update on new guidelines for managing acute and chronic pain in
adults with SCD -- September 27
* An update on state initiatives to screen newborns for SCD -- September
28
* New data on the incidence of SCD in African Americans and other
population groups -- September 28
* A clinical update on treating pulmonary hypertension in SCD patients --
September 28
* A panel on innovative programs to increase awareness, detection and
prevention of SCD -- September 28
* New data on iron overload and new treatment options -- September 29
* A presentation focusing on new uses for old drugs to treat SCD --
September 29
* New information on how to prevent and treat stroke in people with SCD --
September 29
* A panel on education services, including a model on adding education
about SCD sickle cell trait in high schools -- September 29
The SCDAA annual meeting is expected to attract more than 400 patient
advocates, researchers, clinicians, policy makers, and minority health
leaders. More information regarding Sickle Cell Disease, the work of SCDAA,
and the SCDAA convention are available on the SCDAA Web site at
http://www.sicklecelldisease.org or by calling 800-421-8453.
About Sickle Cell Disease: Sickle Cell Disease (SCD) is an inherited blood
disorder that is a major health problem in the United States and worldwide. It
affects various ethnic groups, but is most common in African Americans in the
U.S. In certain sections of the country there are large numbers of Hispanic
individuals with SCD as well. In the general population, one in every 4,000
Americans is born with a form of SCD. Among African Americas, one in every 400
(about 80,000 total) is born with SCD. Over 2.5 million Americans, mostly
African Americans, have sickle cell trait.
About Sickle Cell Disease Association of America, Inc.: For more than 30
years, the Sickle Cell Disease Association of America (SCDAA) and its 100-plus
Member Organizations and affiliates, located in more than 38 states, have
demonstrated how community-based organizations can work as partners with local
and state government agencies in furtherance of national health care
objectives. In collaboration with member and other stakeholder organizations,
SCDAA's national efforts involve five broad categorical areas: research,
public health education, professional health education, patient services and
community services.
CONTACT: Willarda V. Edwards, MD, MBA, President and COO of Sickle Cell
Disease Association of America, Inc., +1-800-421-8453,
wvedwards@sicklecelldisease.org; or Cindy Karra, +1-202-974-5009,
karrac@RuderFinn.com, for Sickle Cell Disease Association of America, Inc.
SOURCE Sickle Cell Disease Association of America, Inc.
Willarda V. Edwards, MD, MBA, President and COO of Sickle Cell Disease
Association of America, Inc., +1-800-421-8453,
wvedwards@sicklecelldisease.org; or Cindy Karra, +1-202-974-5009,
karrac@RuderFinn.com, for Sickle Cell Disease Association of America, Inc.
14:57 20Sep2006 BSW-U.S. Army Taps Dell to Deliver Desktops and Notebooks; Dell Chosen as Part of the... <DELL.O>
U.S. Army Taps Dell to Deliver Desktops and Notebooks; Dell Chosen as Part of the Army's Latest Initiative to Standardize Technology
ROUND ROCK, Texas--(Business Wire)--Sept. 20, 2006--
Dell (NASDAQ:DELL) has been chosen under the Army's
Desktop Mobile Computing (ADMC-2) contract to provide desktop and
notebook computers, displays, printers and peripherals for three
years.
The indefinite-delivery, indefinite-quantity ADMC-2 agreement --
with a purchasing ceiling of $5 billion and options to extend to a
total of 10 years -- is an expansion on the previous hardware contract
awarded to Dell and others in 2001 worth $300 million.
"Because of our long history and direct relationship with the U.S.
Army, we have a thorough understanding of its technology requirements,
both domestically and abroad, and are uniquely positioned to support
the Army's global needs," said Troy West, vice president, Dell federal
business segment. "We have the people, the experience and the
technology to help our military customers, no matter where they are."
About Dell
Dell Inc. (NASDAQ:DELL) listens to customers and delivers
innovative technology and services they trust and value. Uniquely
enabled by its direct business model, Dell sells more systems globally
than any computer company, placing it No. 25 on the Fortune 500.
Company revenue for the past four quarters was $57.4 billion. For more
information, visit www.dell.com. To get Dell news direct, visit
www.dell.com/RSS.
ganador, didn't you put me on the ignore last week.
piss off.
Ganador - the best source of useless information.
Arrow - why such confidence about the loan(s)? Is it based on specific information or feeling?
I am not been a smart ass here.
Arrow - I did account for the fees.
fox, there is a difference between getting a letter of
approval and actually drowing on the money from the bank.
One does not pay anything(less fees) for just an approval.
fox, do not question the medical/scientific side of the
company.
I guess I do not understand a situation when in the country
like Nigeria, where when al presidento says jump and everybody
jump, and with his support of the company/medication/and process, XKEM is still waiting for the loan at least from
Nigerian bank.
It shows that US FDA aproval, or recognition for medication is
irrelevant, if the costumer base here is so small.
Think about the "morning after" pills.
They where available all throughout Europe for years.
(Generating profit by the way).
And here we had all this BS with arests at the airports, etc.
I am not even going to go into the stem cell therapy for
canser patiens. Which also been around for years in
Germany, Swiss and Austria. etc, etc, etc
mcap, - I am not talking about showing of profit by XKEM.
I just find it very alarming that with the support of the
government, they are still did not close the loan, from
at least a Nigerian bank.
All we hear is "it is done, it is done, ..."
And I know for a fact that with the right influence the
loan can be closed and done with within 24 hours.
May be that is so, but after 2000 bubble, not many gamble
on the light at the end of the tunnel.
Not until it can show the money.